生物医药股悉数走强荣昌生物(09995)涨6.65% 机构指医药行业近期震荡调整后估值已回落至相对低位

金吾财讯

Nov 26

金吾财讯 | 生物医药股悉数走强，截至发稿，荣昌生物(09995)涨6.65%，复宏汉霖(02696)涨4.85%，君实生物(01877)涨4.43%，康诺亚-B(02162)涨4.01%，康方生物(09926)涨3.62%，泰格医药(03347)涨3.33%，诺诚健华(09969)涨3.14%。中国银河证券发研报指，2026年政策展望：十五五开局之年，深化三医协同，系统性推进改革。医保支付有望从住院DRGs向门诊APGs拓展，构建全流程闭环管理以提升基金效能；创新药械将获得从研发加速、审评审批优化到医保支付支持的全链条政策助力；集采规则持续优化，在提质扩面中更注重质量与创新平衡，驱动国产替代；通过医疗卫生强基工程推动优质资源下沉基层，强化公共卫生防控与慢性病管理能力，构建优质高效的医疗服务体系，全面提升人民健康水平与预期寿命。总体上，2026年预计政策端仍将驱动医药行业腾笼换鸟、创新升级。该机构看好2026年医药行业投资机会，近期震荡调整后估值已回落至相对低位，有望在2026年重启升势，投资思路上寻找医药硬科技和细分赛道α，推荐关注创新药(BIC和FIC管线龙头)、创新器械(影像、高值耗材、消费器械等)、医疗AI方向，关注医药消费复苏及独立第三方ICL。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2586289514"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586289514\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586289514?lang=en_US&edition=fundamental","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","is_english":false,"pubTime":"2025-11-26 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586289514","market":"sg","top_or_hot":-1,"title":"生物医药股悉数走强 荣昌生物(09995)涨6.65% 机构指医药行业近期震荡调整后估值已回落至相对低位","media":"金吾财讯","content":"<html><body><p>金吾财讯 | 生物医药股悉数走强，截至发稿，<a href=\"https://laohu8.com/S/688331\">荣昌生物</a>(09995)涨6.65%，<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>(02696)涨4.85%，<a href=\"https://laohu8.com/S/688180\">君实生物</a>(01877)涨4.43%，<a href=\"https://laohu8.com/S/02162\">康诺亚-B</a>(02162)涨4.01%，<a href=\"https://laohu8.com/S/09926\">康方生物</a>(09926)涨3.62%，<a href=\"https://laohu8.com/S/300347\">泰格医药</a>(03347)涨3.33%，<a href=\"https://laohu8.com/S/688428\">诺诚健华</a>(09969)涨3.14%。<a href=\"https://laohu8.com/S/06881\">中国银河证券</a>发研报指，2026年政策展望：十五五开局之年，深化三医协同，系统性推进改革。医保支付有望从住院DRGs向门诊APGs拓展，构建全流程闭环管理以提升基金效能；创新药械将获得从研发加速、审评审批优化到医保支付支持的全链条政策助力；集采规则持续优化，在提质扩面中更注重质量与创新平衡，驱动国产替代；通过医疗卫生强基工程推动优质资源下沉基层，强化公共卫生防控与慢性病管理能力，构建优质高效的医疗服务体系，全面提升人民健康水平与预期寿命。总体上，2026年预计政策端仍将驱动医药行业腾笼换鸟、创新升级。该机构看好2026年医药行业投资机会，近期震荡调整后估值已回落至相对低位，有望在2026年重启升势，投资思路上寻找医药硬科技和细分赛道α，推荐关注创新药(BIC和FIC管线龙头)、创新器械(影像、高值耗材、消费器械等)、医疗AI方向，关注医药消费复苏及独立第三方ICL。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>生物医药股悉数走强 荣昌生物(09995)涨6.65% 机构指医药行业近期震荡调整后估值已回落至相对低位</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n生物医药股悉数走强 荣昌生物(09995)涨6.65% 机构指医药行业近期震荡调整后估值已回落至相对低位\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086022552\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">金吾财讯 </p>\n<p class=\"h-time\">2025-11-26 10:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>金吾财讯 | 生物医药股悉数走强，截至发稿，<a href=\"https://laohu8.com/S/688331\">荣昌生物</a>(09995)涨6.65%，<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>(02696)涨4.85%，<a href=\"https://laohu8.com/S/688180\">君实生物</a>(01877)涨4.43%，<a href=\"https://laohu8.com/S/02162\">康诺亚-B</a>(02162)涨4.01%，<a href=\"https://laohu8.com/S/09926\">康方生物</a>(09926)涨3.62%，<a href=\"https://laohu8.com/S/300347\">泰格医药</a>(03347)涨3.33%，<a href=\"https://laohu8.com/S/688428\">诺诚健华</a>(09969)涨3.14%。<a href=\"https://laohu8.com/S/06881\">中国银河证券</a>发研报指，2026年政策展望：十五五开局之年，深化三医协同，系统性推进改革。医保支付有望从住院DRGs向门诊APGs拓展，构建全流程闭环管理以提升基金效能；创新药械将获得从研发加速、审评审批优化到医保支付支持的全链条政策助力；集采规则持续优化，在提质扩面中更注重质量与创新平衡，驱动国产替代；通过医疗卫生强基工程推动优质资源下沉基层，强化公共卫生防控与慢性病管理能力，构建优质高效的医疗服务体系，全面提升人民健康水平与预期寿命。总体上，2026年预计政策端仍将驱动医药行业腾笼换鸟、创新升级。该机构看好2026年医药行业投资机会，近期震荡调整后估值已回落至相对低位，有望在2026年重启升势，投资思路上寻找医药硬科技和细分赛道α，推荐关注创新药(BIC和FIC管线龙头)、创新器械(影像、高值耗材、消费器械等)、医疗AI方向，关注医药消费复苏及独立第三方ICL。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2778985437.USD","symbol_name":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","start_time":0,"source_url":"1970350","article_id":"2586289514","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586289514","pubTimestamp":1764122938,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | 生物医药股悉数走强，截至发稿，荣昌生物 涨6.65%，复宏汉霖涨4.85%，君实生物涨4.43%，康诺亚-B涨4.01%，康方生物涨3.62%，泰格医药涨3.33%，诺诚健华涨3.14%。总体上，2026年预计政策端仍将驱动医药行业腾笼换鸟、创新升级。该机构看好2026年医药行业投资机会，近期震荡调整后估值已回落至相对低位，有望在2026年重启升势，投资思路上寻找医药硬科技和细分赛道α，推荐关注创新药、创新器械、医疗AI方向，关注医药消费复苏及独立第三方ICL。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161726":"生物医药","399441":"生物医药","688331":"荣昌生物","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1515":"抗疫概念","BK1587":"次新股","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1574":"生物医药B类股","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK0239":"医药制造","BK1583":"高瓴概念","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","09995":"荣昌生物","02696":"复宏汉霖","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","03347":"泰格医药","01877":"君实生物","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","09969":"诺诚健华","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1720050803.USD":"安联全方位中国股票基金","09926":"康方生物","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","02162":"康诺亚-B"},"translate_title":"All biopharmaceutical stocks strengthened. Rongchang Biotech (09995) rose 6.65%. Institutions indicate that the valuation of the pharmaceutical industry has fallen back to a relatively low level after recent shocks and adjustments","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1.5,"399441":1.5,"688331":1.5,"09969":0.9,"01877":0.9,"02162":0.9,"09995":1.5,"03347":0.9,"02696":0.9,"09926":0.9},"content_text":"金吾财讯 | 生物医药股悉数走强，截至发稿，荣昌生物(09995)涨6.65%，复宏汉霖(02696)涨4.85%，君实生物(01877)涨4.43%，康诺亚-B(02162)涨4.01%，康方生物(09926)涨3.62%，泰格医药(03347)涨3.33%，诺诚健华(09969)涨3.14%。中国银河证券发研报指，2026年政策展望：十五五开局之年，深化三医协同，系统性推进改革。医保支付有望从住院DRGs向门诊APGs拓展，构建全流程闭环管理以提升基金效能；创新药械将获得从研发加速、审评审批优化到医保支付支持的全链条政策助力；集采规则持续优化，在提质扩面中更注重质量与创新平衡，驱动国产替代；通过医疗卫生强基工程推动优质资源下沉基层，强化公共卫生防控与慢性病管理能力，构建优质高效的医疗服务体系，全面提升人民健康水平与预期寿命。总体上，2026年预计政策端仍将驱动医药行业腾笼换鸟、创新升级。该机构看好2026年医药行业投资机会，近期震荡调整后估值已回落至相对低位，有望在2026年重启升势，投资思路上寻找医药硬科技和细分赛道α，推荐关注创新药(BIC和FIC管线龙头)、创新器械(影像、高值耗材、消费器械等)、医疗AI方向，关注医药消费复苏及独立第三方ICL。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}